# Xenon Pharmaceuticals Inc. (XENE)

**Exchange:** NASDAQ  
**Market cap:** $4.07B  
**Price:** $51.34 (-2.75%)

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $8M | — | -$373M | -$346M | — |
| 2024 | — | — | -$279M | -$234M | — |
| 2023 | — | — | -$214M | -$182M | — |
| 2022 | $9M | — | -$129M | -$125M | — |
| 2021 | $18M | — | -$79M | -$79M | — |
| 2020 | $32M | — | -$31M | -$29M | — |
| 2019 | $7M | — | -$43M | -$42M | — |
| 2017 | $311,000 | — | -$33M | -$31M | — |
| 2016 | $2M | — | -$25M | -$23M | — |
| 2015 | $16M | — | -$9M | -$16M | — |
| 2014 | $28M | — | $11M | $13M | — |
| 2013 | $27M | — | $10M | $12M | — |
| 2012 | $14M | — | -$3M | -$4M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $633M | $51M | $582M | $199M | — |
| 2024 | $798M | $43M | $755M | $143M | — |
| 2023 | $965M | $37M | $928M | $149M | — |
| 2022 | $754M | $33M | $721M | $57M | — |
| 2021 | $572M | $22M | $550M | $176M | — |
| 2020 | $189M | $18M | $171M | $45M | — |
| 2019 | $148M | $56M | $92M | $25M | $11M |
| 2017 | $46M | $10M | $36M | $20M | $6M |
| 2016 | $67M | $4M | $64M | $17M | — |
| 2015 | $64M | $3M | $61M | $59M | — |
| 2014 | $87M | $15M | $73M | $72M | — |
| 2013 | $54M | $30M | -$78M | $38M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$279M | $799,000 | -$280M |
| 2024 | -$181M | $3M | -$184M |
| 2023 | -$151M | $6M | -$157M |
| 2022 | -$101M | $3M | -$104M |
| 2021 | -$70M | $2M | -$72M |
| 2020 | -$48M | $3M | -$51M |
| 2019 | -$5M | $1M | -$6M |
| 2018 | -$35M | $507,000 | -$35M |
| 2017 | -$29M | $315,000 | -$29M |

Source: [CompaniesByCap](https://companiesbycap.com/company/XENE)